Comparator

Analog Semiconductor Market size to grow by USD 32.93 billion from 2023 to 2028, Market growth driven by rising need for automotive electronics- Technavio

Retrieved on: 
Tuesday, January 9, 2024

The potential growth difference for the analog semiconductor market between 2023 and 2028 is USD 32.93 billion.

Key Points: 
  • The potential growth difference for the analog semiconductor market between 2023 and 2028 is USD 32.93 billion.
  • The rising need for automotive electronics is the key factor driving market growth.
  • Get deeper insights into the market size, current market scenario, future growth opportunities, major growth driving factors, the latest trends, and much more.
  • The Semiconductor Market In Military and Aerospace Industry is projected to increase by USD 3.02 billion at a CAGR of 5.56% between 2023 and 2028.

Ivory Dentin Graft™, the First and Only Dentin Graft, Receives CE Mark

Retrieved on: 
Wednesday, September 21, 2022

KEFAR SAVA, Israel, Sept. 21, 2022 /PRNewswire/ -- Developed by Ivory Graft Ltd., the Ivory Dentin Graft™ is a new dentin graft. This graft material has been tailored for use in dental procedures based on the advantages of autologous dentin grafts, documented and proven in years of scientific research and publications. An active organic matrix, Ivory Dentin Graft retains the natural form of the sourced porcine dentin, as well as the protein matrix. Ivory Dentin Graft is CE marked (according to MDR 2017/745).

Key Points: 
  • Ivory Dentin Graft creates a new dentin category of graft substitutes for repair and augmentation of bone defects.
  • KEFAR SAVA, Israel, Sept. 21, 2022 /PRNewswire/ -- Developed by Ivory Graft Ltd ., the Ivory Dentin Graft is a new dentin graft.
  • An active organic matrix, Ivory Dentin Graft retains the natural form of the sourced porcine dentin, as well as the protein matrix.
  • Ivory Dentin Graft is CE marked (according to MDR 2017/745).

6sense and Athena Alliance Partner to Address Boardroom Diversity With Women in Marketing

Retrieved on: 
Thursday, September 15, 2022

SAN FRANCISCO, Sept. 15, 2022 /PRNewswire/ -- Today, 6sense, in partnership with the Athena Alliance, launched The Empowered CMO Board Book aimed at propelling female Chief Market/Marketing Officers (CMOs) to leadership positions where they can have the most impact: in the boardroom. The book provides venture capital, private equity, and corporate board executives with a curated list of more than 60 women CMOs who are qualified and ready to serve on boards.

Key Points: 
  • Recognizing the importance of sponsorship, 6sense invested in more than 100 women CMOs to join the Athena Alliance to accelerate their board readiness and develop their board candidate resume for inclusion in the Board Book.
  • "I really love that 6sense recognizes an issue and is taking action to address it.
  • This collaboration between 6sense and Athena Alliance seeks to bridge this gap by making it easy for seasoned women marketing leaders and those filling board seats to find each other.
  • "Athena has supported over 400 women in gaining board seats, securing almost 1,000 interviews for women leaders along the way.

Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022

Retrieved on: 
Tuesday, March 1, 2022

MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022 regarding its ovarian cancer program.

Key Points: 
  • MENLO PARK, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022 regarding its ovarian cancer program.
  • Corcept will present results from the companys 178-patient, randomized, controlled, Phase 2 study of relacorilant plus nab-paclitaxel for treatment of patients with advanced, platinum-resistant ovarian cancer.
  • Corcept is completing a 178-patient, randomized, controlled, Phase 2 trial of relacorilant plus nab-paclitaxel in patients with recurrent platinum-resistant ovarian cancer.
  • Corcept is studying relacorilant in a variety of serious disorders, including ovarian, adrenal and prostate cancer and Cushings syndrome.

Elemica CEO Recognized as one of the best CEOs of 2021

Retrieved on: 
Wednesday, January 5, 2022

Elemica excels at creating powerful connections within organizations supply chains, Elemica CEO David Muse commented.

Key Points: 
  • Elemica excels at creating powerful connections within organizations supply chains, Elemica CEO David Muse commented.
  • This is a proud moment for me to represent an elite group of individuals here at Elemica.
  • Comparably Awards are based solely on millions of anonymous employee sentiment ratings across multiple categories, said Jason Nazar, CEO of Comparably.
  • The Best CEOs recognizes leaders like Elemica's David Muse for being ranked as top-notch by all employees within their organization.

Bidi Vapor's ENDS Potentially Satisfies Adult Cigarette Smokers, Study Says

Retrieved on: 
Monday, November 29, 2021

Bidi Vapor's ENDS Potentially Satisfies Adult Cigarette Smokers, Study Says

Key Points: 
  • Bidi Vapor's ENDS Potentially Satisfies Adult Cigarette Smokers, Study Says
    Kaival Brands announces the results of a newly published study that found Bidi Vapor's premium electronic nicotine delivery system (ENDS), a disposable device branded BIDI Stick, mimicked the blood levels of nicotine when subjects smoked their usual brand of combustible cigarette, potentially providing a satisfying alternative to cigarette smoking.
  • Comparing published research on other ENDS and tobacco-containing "heat-not-burn" products, study authors said the BIDI Stick may have a greater ability to satisfy adult smokers looking for alternative, non-combustible sources of nicotine.
  • "Based on the findings of a recent clinical study, BIDI Stick ENDS provide adult smokers with the satisfaction they seek from their usual cigarette brand.
  • This study demonstrates that when BIDI Sticks are compared with other ENDS products and Heat-not-Burn products, they are more effective at delivering nicotine to cigarette smokers.

Bidi Vapor's ENDS Satisfies Adult Cigarette Smokers, Study Says

Retrieved on: 
Thursday, November 18, 2021

Comparing published research on other ENDS and tobacco-containing "heat-not-burn" products, study authors said the BIDI Stick may have a greater ability to satisfy adult smokers looking for alternative, non-combustible sources of nicotine.

Key Points: 
  • Comparing published research on other ENDS and tobacco-containing "heat-not-burn" products, study authors said the BIDI Stick may have a greater ability to satisfy adult smokers looking for alternative, non-combustible sources of nicotine.
  • The paper, called"A Randomized, Crossover Clinical Study to Assess Nicotine Pharmacokinetics and Subjective Effects of the BIDI Stick ENDS Compared with Combustible Cigarettes and a Comparator ENDS in Adult Smokers," described the findings from a study in adult smokers aged 21-65 who smoked at least 10 factory-manufactured cigarettes a day.
  • "This study shows that the BIDI Stick can be a meaningful, nicotine delivery alternative for adult smokers aged 21 and older," said Niraj Patel, president and CEO of Bidi Vapor.
  • At Bidi Vapor, innovation is key to our mission, with the BIDI Stick promoting environmental sustainabilitywhile providing a unique vaping experience to adult smokers.

Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer

Retrieved on: 
Friday, September 17, 2021

Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that does not bind to the body's other hormone receptors.

Key Points: 
  • Relacorilant is a non-steroidal, selective modulator of the glucocorticoid receptor that does not bind to the body's other hormone receptors.
  • Corcept is studying relacorilant in a variety of serious disorders, including ovarian, adrenal and castration-resistant prostate cancer and Cushings syndrome.
  • Relacorilant is proprietary to Corcept and is protected by composition of matter and method of use patents.
  • In this press release, forward-looking statements, include those concerning the clinical attributes of relacorilant and its potential benefits in patients with ovarian cancer, results of our Phase 2 trial and our planning for a Phase 3 pivotal trial.

DGAP-News: Dialog Semiconductor Adds Multi-Channel Input Capability to New Nanoamp GreenPAK(TM) Device

Retrieved on: 
Monday, March 15, 2021

The GreenPAK products are extremely cost effective programmable mixed-signal ASICs that are customer designed with GreenPAK Designer Software.

Key Points: 
  • The GreenPAK products are extremely cost effective programmable mixed-signal ASICs that are customer designed with GreenPAK Designer Software.
  • The SLG46811 GreenPAK IC eliminates size constraints with the smallest I2C communication interface, with a multichannel sampling comparator capable of sampling four analog signals.
  • "The SLG46811 is a significant addition to our GreenPAK product family" said John McDonald, Vice President Marketing, CMBU at Dialog Semiconductor.
  • For more information on the SLG46811, please visit https://www.dialog-semiconductor.com/products/greenpak/slg46811
    For more information on Dialog's GreenPAK line, please visit: https://www.dialog-semiconductor.com/products/greenpak
    Dialog, GreenPAK(TM), and the Dialog logo are trademarks of Dialog Semiconductor plc or its subsidiaries.

Talis Provides Update on Regulatory Pathway for Emergency Use Authorization (EUA) of its Talis One™ COVID-19 Test

Retrieved on: 
Monday, March 8, 2021

In late February, the FDAinformed the company that it cannot ensure the comparator assay used in the primary study has sufficient sensitivity to support Taliss EUA application.

Key Points: 
  • In late February, the FDAinformed the company that it cannot ensure the comparator assay used in the primary study has sufficient sensitivity to support Taliss EUA application.
  • Talis intends to initiate its previously planned clinical validation study in a point-of-care environment, with plans to submit an EUA application for the Talis One COVID-19 test in CLIA waived settings early in the second quarter of 2021.
  • The planned clinical validation study was designed with a different comparator assay, which Talis believes will address the FDAs concerns.
  • Given the recent correspondence from the Agency and its stated prioritization of point-of-care platforms, we feel this course of action offers a faster path to market.